Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.52 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23809309 | 1.00 | HTR6 (0.52) | HTR6CNR1CNR2SLC22A12TDP1 | |
| SCHEMBL26581727 | 0.86 | HTR6 (0.54) | HTR6CNR1CNR2 | |
| SCHEMBL26581734 | 0.86 | HTR6 (0.54) | HTR6CNR1CNR2 | |
| SCHEMBL23809381 | 0.82 | SLC22A12 (0.44) | CNR1CNR2SLC22A12 | |
| SCHEMBL23809277 | 0.79 | SLC22A12 (0.47) | CNR1CNR2SLC22A12 | |
| SCHEMBL23809463 | 0.77 | SLC22A12 (0.52) | SLC22A12 | |
| SCHEMBL23809424 | 0.77 | SLC22A12 (0.43) | CNR1CNR2SLC22A12 | |
| SCHEMBL23809482 | 0.76 | SLC22A12 (0.49) | CNR1CNR2SLC22A12 | |
| SCHEMBL23809337 | 0.76 | SLC22A12 (0.47) | CNR1CNR2SLC22A12 | |
| SCHEMBL23809350 | 0.74 | SLC22A12 (0.49) | HTR6CNR2SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | HTR6 1347/4885CNR1 2722/4885CNR2 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.